Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

NCT04992247 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sorrento Therapeutics filed for chapter 11 bankruptcy.

Conditions

Covid19

Interventions

BIOLOGICAL: COVI-MSC
BIOLOGICAL: Placebo

Sponsor

Sorrento Therapeutics, Inc.